HC Wainwright Issues Pessimistic Forecast for IN8bio (NASDAQ:INAB) Stock Price

IN8bio (NASDAQ:INAB) had its target price decreased by HC Wainwright from $12.50 to $8.00 in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for IN8bio’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.59) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at $0.54 EPS.

IN8bio Stock Performance

INAB stock opened at $0.34 on Wednesday. IN8bio has a twelve month low of $0.22 and a twelve month high of $2.48. The company has a quick ratio of 2.66, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. The company has a market cap of $15.69 million, a P/E ratio of -0.45 and a beta of -0.07. The business’s fifty day moving average is $0.30 and its 200-day moving average is $0.67.

Hedge Funds Weigh In On IN8bio

A hedge fund recently raised its stake in IN8bio stock. Sigma Planning Corp lifted its position in IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 851,280 shares of the company’s stock after acquiring an additional 251,600 shares during the period. Sigma Planning Corp owned approximately 1.82% of IN8bio worth $230,000 at the end of the most recent quarter. 92.05% of the stock is owned by institutional investors and hedge funds.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.